VUNO is currently conducting a product-performance assessment for its chest CT AI technology. Credit: CDC on Unsplash.

Medical artificial intelligence (AI) solution company Vuno has received a US patent for its AI-based medical image analysis technology.

Vuno reported in a press release that the patent is approved for a “method of assisting visualisation of lesions in medical images and a device using them.”

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This patent pertains to a technology aimed at simplifying the process of correcting lesion areas identified by medical personnel during the examination of medical images such as X-rays, magnetic resonance imaging scans and computerised tomography (CT) scans in clinical environments.

Vuno’s technology can assist medical staff in focusing on correcting the area of a lesion by presenting multiple options based on the entered lesion.

It can also improve user convenience as the lesion area can be easily modified with the help of a mouse click.

VUNO CEO Lee Ye-ha said: “The patented technology that has been registered this time is a concentration of VUNO’s research and development capabilities and is expected to greatly increase the convenience and efficiency of local medical staff when applied to major products in the future.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The technology is expected to be incorporated in major AI-powered products that the company is planning to introduce for medical imaging to the US market.

These solutions include VUNO Med chest CT AI (VUNO Med -Lung CT AI), which offers AI-assisted interpretation of chest CT images and VUNO Med DeepBrain (VUNO Med-Deep Brain) medical device, which uses AI for brain quantification.

VUNO is currently conducting a product-performance assessment for its chest CT AI technology with the goal of entering the US market.

This evaluation is being carried out under the terms of a clinical research agreement that VUNO signed with Harvard Medical School’s Massachusetts General Hospital in the US in January last year.